From Bio­gen’s buy side to biotech CEO: Josh Man­del-Brehm joins the Po­laris fam­i­ly as a se­r­i­al en­tre­pre­neur in the mak­ing

Last Fri­day, Josh Man­del-Brehm wrapped a 4-year stint at Bio­gen, clos­ing out a chap­ter of his life that end­ed with a run as head of busi­ness de­vel­op­ment for the big biotech. This week he start­ed a new chap­ter as en­tre­pre­neur-in-res­i­dence at Po­laris Part­ners, one of the busiest ven­ture play­ers in biotech. Next stop: CEO of a stealth biotech that’s cur­rent­ly craft­ing a pipeline ahead of the Se­ries A now be­ing put to­geth­er, ex­pect­ed to ar­rive lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER